Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carpo: TP-05 (lotilaner) for Tick Killing in Healthy Volunteers
NCT05387083Phase 2Completed
- Sponsor
- Tarsus Pharmaceuticals, Inc.
- Start
- Dec 2022
- Primary completion
- Jun 2024
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lotilaner in Lyme disease, sponsored by Tarsus Pharmaceuticals, Inc.. Started Dec 2022; status: completed.
02
Drugs
lotilaner
03
Conditions
Lyme disease
Beyond the preview
Go deeper on NCT05387083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05387083.